Virbac SA (VRBCF)
339.23
0.00 (0.00%)
USD |
OTCM |
Dec 13, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.841B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 18.24% |
| Valuation | |
| PE Ratio | 18.72 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.976 |
| Price to Book Value | 2.666 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.417 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3687 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by Asia and Latin America. |
| URL | https://www.virbac.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 25, 2024 |
Ratings
Profile
| Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by Asia and Latin America. |
| URL | https://www.virbac.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 25, 2024 |